Updated interim data from ongoing phase I/IIa study of OpRegen in dry AMD with GA July 21, 2021 No Comments
Eluminex brings in late-stage biosynthetic cornea from Fibrogen in $108M deal July 20, 2021 By Elise Mak No Comments In a deal worth up to $108 million, ophthalmic startup Eluminex Biosciences Ltd. has licensed the global rights to Fibrogen Inc.’s biosynthetic cornea derived from recombinant human collagen (RHC) type III intended to tackle corneal blindness.Read More
Positive phase I data for UBX-1325 in patients with advanced vascular eye disease July 7, 2021 No Comments
Marinomed reports phase II topline data on Tacrosolv eye drops for allergic rhinoconjunctivitis July 1, 2021 No Comments
Peking University Third Hospital, Chigenovo Co. describe therapies including CYP4V2 and RdCVF June 28, 2021 No Comments
Applied Genetic Technologies reports 12-month data from phase I/II achromatopsia trials June 25, 2021 No Comments
Gemini reports data from ongoing phase IIa study on GEM-103 in GA secondary to dry AMD June 23, 2021 No Comments
RSS
